Vlad Vitoc, MD, MBA
His experience includes managing and supporting over 20 early, launch, and mature stage compounds, amongst which targeted therapies and immune therapies, across more than 25 tumor types – amongst which colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, renal cell carcinoma. In his previous role at Barricade Therapeutics, he served as the Chief Business Officer and SVP Medical Affairs, leading the capitalization efforts and the pharmaceutical business development activities. At Puma Biotechnology, he served as VP Medical Affairs and built the Medical organization supporting the launch of NERLYNX (neratinib) in extended adjuvant breast cancer. Before Puma, Dr. Vitoc was the Executive Medical Director for pipeline products at Incyte Corporation, establishing the medical affairs support for compounds transitioning from preclinical to phase I and II clinical trials. Before that, he was Sr Medical Director at Astellas Pharma Inc., supporting the launch and development of XTANDI (enzalutamide), the life cycle management of TARCEVA (erlotinib), as well as pipeline compounds. Earlier in his career, he served in commercial strategic analysis and planning leadership roles centered on life cycle management, business development, and forecasting at Cephalon Oncology, Novartis Oncology, Bayer Oncology, and Pharmacia & Upjohn. He obtained his medical training at the University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj-Napoca, Romania, and his MBA at the University of South Carolina.
Joe Dillon, PH.D., MBA
Mr. Relovsky was the founding and managing partner for Clarity Global Solutions LLC, a consulting firm specializing in commercial value development and operational support to biotech and pharmaceutical companies, with primary focus on early-mid stage asset development and product planning building commercial value. Additionally, CGS specializes in therapeutic area market development and engagement, Medical Affairs and Commercial Operations management, with particular focus on commercialization and launch preparation.
Mr. Relovsky began his career in Finance for Squibb-Novo, Inc. (now Novo Nordisk Pharmaceuticals, Inc.) and over the years has held various management positions, with increasing levels of responsibility, including leading operations functional areas, Product Planning and Marketing, addressing both company-wide and product level initiatives. Most recently, Mr. Relovsky has established and led the Commercial Operations and launch planning for ARS Pharmaceuticals, Inc. for an intranasal form of epinephrine (ARS-1). Prior to ARS, he led Medical Affairs Operations for Puma Biotechnology, Inc. through the launch of NERLYNX (neratinib), a tyrosine kinase inhibitor approved for the treatment of breast cancer. He has also held positions leading Commercial Operations for Somaxon Pharmaceuticals, Inc. which launched SILENOR (doxepin) for the treatment of insomnia; and Marketing for Cephalon, Inc. where he established the oncology franchise that included the product re-launch of TRISENOX (arsenic trioxide) in acute promyelocytic leukemia (APL) and launch of TREANDA (bendamustine) in two indications: chronic lymphocytic leukemia (CLL) and indolent non-hodgkin lymphoma (NHL). Other previous positions include product planning and marketing with Salmedix, Inc., Maxim Pharmaceuticals, Inc.; and commercial operations with Agouron Pharmaceutics, Inc. all based in San Diego, CA; and IMS Health (now IQVIA). Additionally, Mr. Relovsky held the role of Vice President, Development & Board Member for the American Melanoma Foundation.
Mr. Relovsky holds a Bachelor of Science, Business Administration and Finance from Drexel University in Philadelphia, PA.
Wayne Klohs, PH.D.
In five years at Astellas, Dr. Klohs helped build Oncology into a global business with several marketed products including Tarceva® and Xtandi® and helped build a robust oncology pipeline through in-licensing, the acquisition of OSI, and internal discovery. He was responsible for the successful filings of NDAs and MAAs for Xtandi (enzalutamide) and Tarceva (sNDA). Dr. Klohs’s previous experience includes acting head of Oncology Clinical Sciences at Takeda Global R&D and Executive Director of Oncology Drug Development at Pfizer, Inc. At Takeda, he led both early and late-stage Development Teams in Oncology, while at Pfizer, he was responsible for Development Teams from mid-Discovery through POC with additional experience in NDA filing of pentostatin/Nipent. Dr. Klohs led development teams at Pfizer and Parke-Davis to more than 14 successful IND filings and Phase 1 starts as well as leading late stage programs in biologics including monoclonal antibodies and an oncolytic adenovirus. Prior to his experience in drug development for oncology, he led discovery efforts at Warner-Lambert/Parke Davis Pharmaceutical Research in oncology for 16 years in a number of areas including antiangiogenic agents, multiple drug resistance, histone deacetylase inhibitors, and antifolates.